"Two weeks after the injection, participants who received DMT enjoyed a greater reduction in depressive symptoms than those who received placebo. Tommaso Barba, a PhD candidate at Imperial College London and one of the study's authors, emphasised the role of therapists in the study to help prepare patients for the experience and help them understand it and integrate it into their lives after it was over."
"The synthetic DMT formulation used in the trial, rather, produces a short but intense 30-minute psychedelic experience that does not induce vomiting. Dr Daniel Perkins, a senior research fellow at the University of Melbournes psychedelics research and therapeutics unit, said that the vomiting element of ayahuasca can have value on its own, although not everyone vomits when they have traditional ayahuasca compounds."
A phase II clinical trial sponsored by Small Pharma (now Cybin UK) and led by Dr David Erritzoe at Imperial College London tested DMT as a depression treatment. Thirty-four participants received either a synthetic DMT injection or placebo, with all receiving psychotherapeutic support. Two weeks post-injection, DMT recipients showed greater depressive symptom reduction than placebo recipients. The synthetic formulation produces a 30-minute intense psychedelic experience without the nausea associated with traditional ayahuasca tea. Researchers emphasize therapist involvement in preparation, experience guidance, and post-experience integration. While results are promising, researchers acknowledge the trial's small scale and preliminary nature, indicating further research is needed.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]